332099-14-6

Basic information

• Product Name: 2-METHYL-4H-THIENO[3,2-B]PYRROLE-5-CARBOXYLIC ACID
• Synonyms: 2-METHYL-4H-THIENO[3,2-B]PYRROLE-5-CARBOXYLIC ACID
• CAS NO: 332099-14-6
• Molecular Formula: C8H7NO2S
• Molecular Weight: 181.21
• Mol File: 332099-14-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2-METHYL-4H-THIENO[3,2-B]PYRROLE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHYL-4H-THIENO[3,2-B]PYRROLE-5-CARBOXYLIC ACID(332099-14-6)
• EPA Substance Registry System: 2-METHYL-4H-THIENO[3,2-B]PYRROLE-5-CARBOXYLIC ACID(332099-14-6)

Safety Data

• Hazardous Substances Data: 332099-14-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-METHYL-4H-THIENO[3,2-B]PYRROLE-5-CARBOXYLIC ACID is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs due to its unique molecular structure and potential biological activities.
Used in Agrochemical Industry:
In the agrochemical sector, 2-METHYL-4H-THIENO[3,2-B]PYRROLE-5-CARBOXYLIC ACID serves as an intermediate in the production of agrochemicals, potentially enhancing crop protection and management through its incorporation into new chemical formulations.
Used as an Antibacterial Agent:
2-METHYL-4H-THIENO[3,2-B]PYRROLE-5-CARBOXYLIC ACID is studied for its potential as an antibacterial agent, suggesting its use in combating bacterial infections, although further research is necessary to understand its full potential and mechanisms of action.
Used as an Antifungal Agent:
Similarly, this compound is being investigated for its antifungal properties, indicating its possible application in treating fungal infections and controlling fungal growth in various settings, pending further exploration into its efficacy and safety.

Upstream product

• 238749-54-7 ethyl 2-methyl-4H-thieno[3,2-b]pyrrole-5-carboxylate 

Relevant articles and documents

FLUORESCENT COMPOUND AND LABELING AGENT COMPRISING THE SAME

A novel fluorescent compound having a high light fastness, high fluorescence quantum yield and sharp absorption spectrum, which emits fluorescence having a wavelength in long wavelength region, as well as its use as a labeling agent, is disclosed. In Form

FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE

This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O?X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.

USE OF FUSED PYRROLE CARBOXYLIC ACIDS FOR THE TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES AS D-AMINO ACID OXIDASE INHIBITORS

The present invention provides the use of fused pyrrole carboxylic acids of formula (I) for the manufacture of a medicament to inhibit D-amino acid oxidase, particularly for the treatment of neurodegenerative and psychiatric disorders or diseases; certain

Use of glycogen phosphorylase inhibitors

The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

This invention relates to compounds of Formula I or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compou